ArticleJournal of inflammation research2025
The Associations of Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammatory Index with the Severity and Prognosis of Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The neutrophil-to-lymphocyte ratio: a psychoneuroimmunological nexus linking depression and cardiovascular comorbidity.European archives of psychiatry and clinical neuroscience · 2026Article
- Investigation of Prognostic Factors in Patients With Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.European journal of neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammatory index (SII) are biological indicators that reflect the inflammatory state in some immune diseases. This study investigated the associations of the NLR, MLR, PLR, and SII with the severity and prognosis of autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A). Patients and Methods: This retrospective study analyzed the data of 62 patients with GFAP-A at the First Affiliated Hospital of Zhengzhou University from January 2020 to August 2024. The Clinical Assessment Scale for Autoimmune Encephalitis (CASE) was used to assess the disease severity at admission and patients were categorized into mild (CASE ≤4) or severe (CASE ≥5) groups. The modified Rankin Scale (mRS) was used to assess the patients' conditions at discharge and follow-up. Patients were categorized into the good (mRS ≤2) or poor (mRS ≥3) prognosis groups at 1-year follow-up. Risk factors affecting the severity and prognosis of GFAP-A were analyzed using binary logistic regression analysis. Results: The NLR, MLR, PLR, and SII were significantly higher in the severe group than in the mild group. The NLR (OR=1.238, 95% CI: 1.003-1.473, P=0.01) was an independent risk factor for the severity of GFAP-A and was positively correlated with the CASE score (r=0.365, P=0.003). The best cut-off NLR for predicting the severity of GFAP-A was 3.05, with a sensitivity of 80%, specificity of 57.1%, and AUC of 0.729 (95% CI: 0.600-0.858, P=0.004). The mRS score at discharge (OR=7.966, 95% CI: 1.120-56.658; P=0.038) was an independent risk factor for poor prognosis one year after discharge. In addition, the NLR, MLR, PLR, and SII at admission and reduction of the PLR after immunotherapy were not associated with patient prognosis (P > 0.05). Conclusion: The NLR, an objective, inexpensive, and clinically accessible biomarker, is positively associated with the CASE score, that is, with the severity of GFAP-A. Therefore, the NLR can be used to identify patients with potentially severe GFAP-A at an early stage, thus optimizing the clinical treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.